-
1
-
-
0027382941
-
Cancer of the ovary
-
Cannistra SA: Cancer of the ovary. N Engl J Med 329:1550-1559, 1993
-
(1993)
N Engl J Med
, vol.329
, pp. 1550-1559
-
-
Cannistra, S.A.1
-
2
-
-
0030054309
-
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
-
McGuire W, Hoskins W, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
-
(1996)
N Engl J Med
, vol.334
, pp. 1-6
-
-
McGuire, W.1
Hoskins, W.2
Brady, M.F.3
-
3
-
-
0028237309
-
Treatment of ovarian cancer: Current status
-
Ozols RF: Treatment of ovarian cancer: Current status. Semin Oncol 21:1-9, 1994
-
(1994)
Semin Oncol
, vol.21
, pp. 1-9
-
-
Ozols, R.F.1
-
5
-
-
0027999966
-
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
-
Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
-
(1994)
J Clin Oncol
, vol.12
, pp. 2654-2666
-
-
Eisenhauer, E.A.1
Ten Bokkel Huinink, W.W.2
Swenerton, K.D.3
-
6
-
-
0009685829
-
Is cisplatin-taxol (PT) the standard treatment in advanced ovarian cancer?
-
abstr
-
Bertelsen K, Kaern J, Simonsen E, et al: Is cisplatin-taxol (PT) the standard treatment in advanced ovarian cancer? Eur J Cancer 33:614, 1998 (abstr)
-
(1998)
Eur J Cancer
, vol.33
, pp. 614
-
-
Bertelsen, K.1
Kaern, J.2
Simonsen, E.3
-
7
-
-
0030900145
-
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
-
ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997
-
(1997)
J Clin Oncol
, vol.15
, pp. 2183-2193
-
-
Ten Bokkel Huinink, W.1
Gore, M.2
Carmichael, J.3
-
8
-
-
0028153230
-
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Onclogy Group study
-
Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Onclogy Group study. J Clin Oncol 12:1748-1753, 1994
-
(1994)
J Clin Oncol
, vol.12
, pp. 1748-1753
-
-
Thigpen, J.T.1
Blessing, J.A.2
Ball, H.3
-
9
-
-
0026086870
-
Second-line platinum therapy in patients with previously treated with cisplatin
-
Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
-
(1991)
J Clin Oncol
, vol.9
, pp. 389-393
-
-
Markman, M.1
Rothman, R.2
Hakes, T.3
-
10
-
-
0025860057
-
Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience
-
Omura G, Brady MF, Homesley HD, et al: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 9:1138-1150, 1991
-
(1991)
J Clin Oncol
, vol.9
, pp. 1138-1150
-
-
Omura, G.1
Brady, M.F.2
Homesley, H.D.3
-
11
-
-
0019284266
-
1,2-diaminocyclohexane platinum derivatives of potential clinical values
-
Mathé G, Muggia F (eds): Berlin, Springer-Verlag
-
Burchenal J, Irani G, Kern K, et al: 1,2-diaminocyclohexane platinum derivatives of potential clinical values, in Mathé G, Muggia F (eds): Recent Results in Cancer Research: Cancer Chemo-and Immuno-pharmacology. Berlin, Springer-Verlag, 1980, pp 146-155
-
(1980)
Recent Results in Cancer Research: Cancer Chemo-and Immuno-pharmacology
, pp. 146-155
-
-
Burchenal, J.1
Irani, G.2
Kern, K.3
-
12
-
-
0027146423
-
In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin
-
Pendyala L, Creaven PJ: In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53:5970-5976, 1993
-
(1993)
Cancer Res
, vol.53
, pp. 5970-5976
-
-
Pendyala, L.1
Creaven, P.J.2
-
13
-
-
0031855988
-
Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin
-
Fink D, Nebel S, Norris PS, et al: Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer 77:741-746, 1998
-
(1998)
Int J Cancer
, vol.77
, pp. 741-746
-
-
Fink, D.1
Nebel, S.2
Norris, P.S.3
-
14
-
-
0009724281
-
Cross-resistance patterns of cell lines selected with platinum suggest differences in the activities and mechanisms of resistance of platinum analogues
-
abstr
-
Alvarez M, Ortuzar W, Rixe O, et al: Cross-resistance patterns of cell lines selected with platinum suggest differences in the activities and mechanisms of resistance of platinum analogues. Proc Annu Meet Am Assoc Cancer Res 35:439, 1994 (abstr)
-
(1994)
Proc Annu Meet Am Assoc Cancer Res
, vol.35
, pp. 439
-
-
Alvarez, M.1
Ortuzar, W.2
Rixe, O.3
-
15
-
-
0000460127
-
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel
-
Rixe O, Ortuzar W, Alvarez M, et al: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52:1855-1865, 1996
-
(1996)
Biochem Pharmacol
, vol.52
, pp. 1855-1865
-
-
Rixe, O.1
Ortuzar, W.2
Alvarez, M.3
-
16
-
-
0000417489
-
Comparison of the activity of cisplatin (CP) and oxaliplatin (OXALI) alone or in combination in parental and drug resistant sublines
-
abstr
-
Ortuzar W, Paull K, Rixe O, et al: Comparison of the activity of cisplatin (CP) and oxaliplatin (OXALI) alone or in combination in parental and drug resistant sublines. Proc Annu Meet Am Assoc Cancer Res 35:332, 1994 (abstr)
-
(1994)
Proc Annu Meet Am Assoc Cancer Res
, vol.35
, pp. 332
-
-
Ortuzar, W.1
Paull, K.2
Rixe, O.3
-
17
-
-
0000360781
-
Experimental study of three platinum complexes: CDDP, CBDCA and L-OHP on L1210 leukemia - Alternate or simultaneous association of two platinum complexes
-
abstr
-
Mathé G, Chenu E, Bourut C, et al: Experimental study of three platinum complexes: CDDP, CBDCA and L-OHP on L1210 leukemia - Alternate or simultaneous association of two platinum complexes. Proc Annu Meet Am Assoc Cancer Res 30:471, 1989 (abstr)
-
(1989)
Proc Annu Meet Am Assoc Cancer Res
, vol.30
, pp. 471
-
-
Mathé, G.1
Chenu, E.2
Bourut, C.3
-
18
-
-
0025020085
-
Phase I study of oxaliplatin in patients with advanced cancer
-
Extra JM, Espie M, Calvo F, et al: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25: 299-303, 1990
-
(1990)
Cancer Chemother Pharmacol
, vol.25
, pp. 299-303
-
-
Extra, J.M.1
Espie, M.2
Calvo, F.3
-
19
-
-
0343046558
-
Oxaliplatin (L-OHP): Global safety in 682 patients (pts)
-
abstr 933
-
Brienza S, Vignoud J, Itzhaki M, et al: Oxaliplatin (L-OHP): Global safety in 682 patients (pts). Eur J Cancer 31A:S194, 1995 (suppl, abstr 933)
-
(1995)
Eur J Cancer
, vol.31 A
, Issue.SUPPL.
-
-
Brienza, S.1
Vignoud, J.2
Itzhaki, M.3
-
21
-
-
8944230189
-
Loss of DNA mismatch repair in acquired resistance to cisplatin
-
Aebi S, Kurdihaidar B, Gordon R, et al: Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 53:3087-3090, 1996
-
(1996)
Cancer Res
, vol.53
, pp. 3087-3090
-
-
Aebi, S.1
Kurdihaidar, B.2
Gordon, R.3
-
22
-
-
15444350120
-
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
-
Fink D, Zheng H, Nebel S, et al: In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57:1841-1845, 1997
-
(1997)
Cancer Res
, vol.57
, pp. 1841-1845
-
-
Fink, D.1
Zheng, H.2
Nebel, S.3
-
23
-
-
0002243040
-
Oxalatoplatinum (L-OHP): Experimental and clinical studies
-
Howell S (ed) New York, New York, Plenum Press
-
Misset JL, Kidani Y, Gastiaburu J et al, et al: Oxalatoplatinum (L-OHP): Experimental and clinical studies, in Howell S (ed): Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. New York, New York, Plenum Press, 1991, pp 369-375
-
(1991)
Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy
, pp. 369-375
-
-
Misset, J.L.1
Kidani, Y.2
Gastiaburu, J.3
-
24
-
-
0030480745
-
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer
-
Chollet P, Bensmaine A, Brienza S, et al: Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7:1065-1070, 1996
-
(1996)
Ann Oncol
, vol.7
, pp. 1065-1070
-
-
Chollet, P.1
Bensmaine, A.2
Brienza, S.3
-
25
-
-
0016799829
-
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials
-
Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 31:103-115, 1975
-
(1975)
Biometrics
, vol.31
, pp. 103-115
-
-
Pocock, S.J.1
Simon, R.2
-
26
-
-
0019365237
-
Reporting results of cancer treatment
-
Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
-
(1981)
Cancer
, vol.47
, pp. 207-214
-
-
Miller, A.B.1
Hoogstraten, B.2
Staquet, M.3
-
27
-
-
0030698757
-
Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients
-
Eisenhauer EA, Vermorken JB, van Glabbeke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Ann Oncol 8:963-968, 1997
-
(1997)
Ann Oncol
, vol.8
, pp. 963-968
-
-
Eisenhauer, E.A.1
Vermorken, J.B.2
Van Glabbeke, M.3
-
28
-
-
10544229791
-
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
-
Creemers GJ, Bolis G, Gore M, et al: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 14:3056-3061, 1996
-
(1996)
J Clin Oncol
, vol.14
, pp. 3056-3061
-
-
Creemers, G.J.1
Bolis, G.2
Gore, M.3
-
29
-
-
0000626027
-
A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer
-
abstr 769
-
Armstrong D, Rowinsky EK, Donehower R, et al: A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 14:275a, 1995 (abstr 769)
-
(1995)
Proc Am Soc Clin Oncol
, vol.14
-
-
Armstrong, D.1
Rowinsky, E.K.2
Donehower, R.3
-
30
-
-
9244247616
-
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
-
Kudelka A, Tresukosol D, Edwards CL, et al: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14:1552-1557, 1996
-
(1996)
J Clin Oncol
, vol.14
, pp. 1552-1557
-
-
Kudelka, A.1
Tresukosol, D.2
Edwards, C.L.3
-
31
-
-
0000391321
-
Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial
-
abstr 763
-
Gordon A, Bookman MA, Malmstrom H, et al: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial. Proc Am Soc Clin Oncol 15:282a, 1996 (abstr 763)
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
-
-
Gordon, A.1
Bookman, M.A.2
Malmstrom, H.3
-
32
-
-
0031786482
-
Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label, phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
-
Bookman MA, Malmstrom H, Bolis G, et al: Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label, phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16:3345-3352, 1998
-
(1998)
J Clin Oncol
, vol.16
, pp. 3345-3352
-
-
Bookman, M.A.1
Malmstrom, H.2
Bolis, G.3
-
33
-
-
0027999654
-
Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer
-
Francis P, Schneider J, Hann L, et al: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12:2301-2308, 1994
-
(1994)
J Clin Oncol
, vol.12
, pp. 2301-2308
-
-
Francis, P.1
Schneider, J.2
Hann, L.3
-
34
-
-
0028900053
-
Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer
-
Piccart M, Gore M, ten Bokkel Huinink WW, et al: Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87:676-681, 1995
-
(1995)
J Natl Cancer Inst
, vol.87
, pp. 676-681
-
-
Piccart, M.1
Gore, M.2
Ten Bokkel Huinink, W.W.3
-
35
-
-
0028810460
-
Docetaxel in advanced ovarian cancer: Preliminary results from three phase II trials-EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center
-
Kaye SB, Piccart M, Aapro M, et al: Docetaxel in advanced ovarian cancer: Preliminary results from three phase II trials-EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center. Eur J Cancer 31A:S14-S17, 1995 (suppl 4)
-
(1995)
Eur J Cancer
, vol.31 A
, Issue.4 SUPPL.
-
-
Kaye, S.B.1
Piccart, M.2
Aapro, M.3
-
36
-
-
0027521254
-
Hexamethylmelamine/ altretamine as second-line therapy for epithelial ovarian carcinoma
-
Moore D, Valea F, Grumpler LS, et al: Hexamethylmelamine/ altretamine as second-line therapy for epithelial ovarian carcinoma. Gynecol Oncol 51:109-112, 1993
-
(1993)
Gynecol Oncol
, vol.51
, pp. 109-112
-
-
Moore, D.1
Valea, F.2
Grumpler, L.S.3
-
37
-
-
0031193915
-
Hexamethylmelamine as a single second line agent in ovarian cancer: Follow-up report and review of the literature
-
Manetta A, Krishnansu T, Edwards S, et al: Hexamethylmelamine as a single second line agent in ovarian cancer: Follow-up report and review of the literature. Gynecol Oncol 66:20-26, 1997
-
(1997)
Gynecol Oncol
, vol.66
, pp. 20-26
-
-
Manetta, A.1
Krishnansu, T.2
Edwards, S.3
-
38
-
-
0027066977
-
Hexamethylmelamine as second line therapy in platin-resistant ovarian cancer
-
Vergote I, Himmelmann A, Bo Frankendal PH, et al: Hexamethylmelamine as second line therapy in platin-resistant ovarian cancer. Gynecol Oncol 47:282-286, 1992
-
(1992)
Gynecol Oncol
, vol.47
, pp. 282-286
-
-
Vergote, I.1
Himmelmann, A.2
Bo Frankendal, P.H.3
-
39
-
-
0032103330
-
Altretamine (Hexamethylmelamine) in platinum resistant and platinum refractory ovarian cancer: A Gynecologic Oncology Group phase II trial
-
Markman M, Blessing JA, Moore D, et al: Altretamine (Hexamethylmelamine) in platinum resistant and platinum refractory ovarian cancer: A Gynecologic Oncology Group phase II trial. Gynecol Oncol 69:226-229, 1998
-
(1998)
Gynecol Oncol
, vol.69
, pp. 226-229
-
-
Markman, M.1
Blessing, J.A.2
Moore, D.3
-
40
-
-
0031894188
-
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study
-
Rose G, Blessing A, Mayer R, et al: Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 16:405-410, 1998
-
(1998)
J Clin Oncol
, vol.16
, pp. 405-410
-
-
Rose, G.1
Blessing, A.2
Mayer, R.3
-
41
-
-
0028088853
-
Oral etoposide is active against platinum-resistant epithelial ovarian cancer
-
Hoskins J, Swenerton KD: Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12:60-63, 1994
-
(1994)
J Clin Oncol
, vol.12
, pp. 60-63
-
-
Hoskins, J.1
Swenerton, K.D.2
-
42
-
-
0027295694
-
Low-dose oral etoposide in epithelial cancer of the ovary
-
Marzola M, Zuchetti M, Colombo N, et al: Low-dose oral etoposide in epithelial cancer of the ovary. Ann Oncol 4:517-519, 1993
-
(1993)
Ann Oncol
, vol.4
, pp. 517-519
-
-
Marzola, M.1
Zuchetti, M.2
Colombo, N.3
-
43
-
-
0026599140
-
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease
-
Markman M, Hakes T, Reichman B, et al: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 10:243-248, 1992
-
(1992)
J Clin Oncol
, vol.10
, pp. 243-248
-
-
Markman, M.1
Hakes, T.2
Reichman, B.3
-
44
-
-
0024422604
-
Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group study
-
Sutton GP, Blessing JA, Homesley HD, et al: Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 7:1672-1676, 1989
-
(1989)
J Clin Oncol
, vol.7
, pp. 1672-1676
-
-
Sutton, G.P.1
Blessing, J.A.2
Homesley, H.D.3
-
45
-
-
0030757254
-
Efficacy of carboplatin plus primary prophylactic filgrastim (granulocyte colony stimulating factor) in relapsed ovarian cancer: A study of the Gynecologic Study Group of the Comprehensive Cancer Center Limburg
-
Wils J, Geuns HV, Wals J, et al: Efficacy of carboplatin plus primary prophylactic filgrastim (granulocyte colony stimulating factor) in relapsed ovarian cancer: A study of the Gynecologic Study Group of the Comprehensive Cancer Center Limburg. Anticancer Drugs 8:432-435, 1997
-
(1997)
Anticancer Drugs
, vol.8
, pp. 432-435
-
-
Wils, J.1
Geuns, H.V.2
Wals, J.3
-
46
-
-
0021048258
-
Phase II study of JM 8, a new platinum analog in advanced ovarian carcinoma
-
Evans BD, Rajo KS, Calvert AH, et al: Phase II study of JM 8, a new platinum analog in advanced ovarian carcinoma. Cancer Treat Rep 67:997-1000, 1983
-
(1983)
Cancer Treat Rep
, vol.67
, pp. 997-1000
-
-
Evans, B.D.1
Rajo, K.S.2
Calvert, A.H.3
-
47
-
-
0022514448
-
Phase II study of carboplatin in patients with ovarian carcinoma: A National Cancer Institute of Canada Trials Groups Study
-
Eisenhauer EA, Swenerton KD, Sturgeon J, et al: Phase II study of carboplatin in patients with ovarian carcinoma: A National Cancer Institute of Canada Trials Groups Study. Cancer Treat Rep 70:1195-1198, 1986
-
(1986)
Cancer Treat Rep
, vol.70
, pp. 1195-1198
-
-
Eisenhauer, E.A.1
Swenerton, K.D.2
Sturgeon, J.3
-
48
-
-
0028020890
-
Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients
-
Lund B, Hansen OP, Theilade K, et al: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86:1530-1533, 1994
-
(1994)
J Natl Cancer Inst
, vol.86
, pp. 1530-1533
-
-
Lund, B.1
Hansen, O.P.2
Theilade, K.3
-
49
-
-
0000707103
-
Phase III of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study #132
-
abstr 1257
-
Muggia F, Braly P, Brady MF, et al: Phase III of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study #132. Proc Am Soc Clin Oncol 16:352a, 1997 (abstr 1257)
-
(1997)
Proc Am Soc Clin Oncol
, vol.16
-
-
Muggia, F.1
Braly, P.2
Brady, M.F.3
-
50
-
-
9544238078
-
Phase D study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum-resistant disease
-
Bajetta E, Di Leo A, Biganzoli L, et al: Phase D study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 14:2546-2551, 1996
-
(1996)
J Clin Oncol
, vol.14
, pp. 2546-2551
-
-
Bajetta, E.1
Di Leo, A.2
Biganzoli, L.3
-
51
-
-
0011811413
-
Phase I study of irinotecan (cpt-11) in combination with cisplatin (cddp) on cervical carcinoma
-
abstr
-
Sugiyama T, Takeuchi S, Yakushiji M: Phase I study of irinotecan (cpt-11) in combination with cisplatin (cddp) on cervical carcinoma. Proc Am Soc Clin Oncol 13:856a, 1994 (abstr)
-
(1994)
Proc Am Soc Clin Oncol
, vol.13
-
-
Sugiyama, T.1
Takeuchi, S.2
Yakushiji, M.3
-
53
-
-
0004482591
-
A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer
-
abstr
-
Underbill C, Parnis FX, Highley M, et al: A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 15:290a, 1996 (abstr)
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
-
-
Underbill, C.1
Parnis, F.X.2
Highley, M.3
-
54
-
-
0028330988
-
High-dose intensity regimens with epirubicin in ovarian cancer
-
Vermorken JB, Bolis G, Van Rijswijk REN, et al: High-dose intensity regimens with epirubicin in ovarian cancer. Semin Oncol 21:17-22, 1994
-
(1994)
Semin Oncol
, vol.21
, pp. 17-22
-
-
Vermorken, J.B.1
Bolis, G.2
Van Rijswijk, R.E.N.3
-
55
-
-
0003195061
-
Oxaliplatin (L-OHP) phase II study in platinum (PT) pretreated advanced ovarian cancer (AOC): Preliminary results
-
abstr 1405
-
Dieras V, Bougnoux P, Petit T, et al: Oxaliplatin (L-OHP) phase II study in platinum (PT) pretreated advanced ovarian cancer (AOC): Preliminary results. Proc Am Soc Clin Oncol 17:364a, 1998 (abstr 1405)
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Dieras, V.1
Bougnoux, P.2
Petit, T.3
-
56
-
-
0032859533
-
Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate use experience
-
Faivre S, Kalla S, Cvitkovic E, et al: Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate use experience. Ann Oncol 10:1125-1128, 1999
-
(1999)
Ann Oncol
, vol.10
, pp. 1125-1128
-
-
Faivre, S.1
Kalla, S.2
Cvitkovic, E.3
-
57
-
-
0003610856
-
Paclitaxel (PXL)-oxaliplatin (L-OHP): A feasible active combination in heavily pretreated advanced ovarian carcinoma (ADOVCA) patients (PTS)
-
abstr 1378
-
Kalla S, Faivre S, Bensmaine A, et al: Paclitaxel (PXL)-oxaliplatin (L-OHP): A feasible active combination in heavily pretreated advanced ovarian carcinoma (ADOVCA) patients (PTS). Proc Am Soc Clin Oncol 17:357a, 1998 (abstr 1378)
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Kalla, S.1
Faivre, S.2
Bensmaine, A.3
-
58
-
-
0001430095
-
Multicentric phase H-III trial of oxaliplatin (LOHP) versus cisplatin (P) both in association with cyclophosphamide (C) in the treatment of advanced ovarian cancer (AOC): Toxicity efficacy results
-
abstr 1266
-
Misset J, Chollet P, Vennin P, et al: Multicentric phase H-III trial of oxaliplatin (LOHP) versus cisplatin (P) both in association with cyclophosphamide (C) in the treatment of advanced ovarian cancer (AOC): Toxicity efficacy results. Proc Am Soc Clin Oncol 16:354a, 1997 (abstr 1266)
-
(1997)
Proc Am Soc Clin Oncol
, vol.16
-
-
Misset, J.1
Chollet, P.2
Vennin, P.3
-
59
-
-
0343247791
-
Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer
-
Soulié P, Bensmaine A, Garrino C, et al: Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 33:1400-1406, 1997
-
(1997)
Eur J Cancer
, vol.33
, pp. 1400-1406
-
-
Soulié, P.1
Bensmaine, A.2
Garrino, C.3
-
60
-
-
0003528777
-
Feasability study of the paclitaxel (PXL), oxaliplatin (LOHP) and cisplatin (CDDP) combination in advanced ovarian cancer (AOC) patients (PTS)
-
abstr 1409
-
Delaloge S, Laadem A, Chouaki N, et al: Feasability study of the paclitaxel (PXL), oxaliplatin (LOHP) and cisplatin (CDDP) combination in advanced ovarian cancer (AOC) patients (PTS). Proc Am Soc Clin Oncol 18:365a, 1999 (abstr 1409)
-
(1999)
Proc Am Soc Clin Oncol
, vol.18
-
-
Delaloge, S.1
Laadem, A.2
Chouaki, N.3
|